Biopôle is delighted to partner with Lenz & Staehelin for LEGAL ESSENTIALS, an exclusive series of three interactive seminars focusing on intellectual property (IP) protection, equity incentive plans, taxation and stakeholder relations management.

At the first session, on Thursday 6 April, Sevan Antreasyan and Emilie Jacot-Guillarmod will help us understand how to secure your company’s IP in a licensing context while avoiding the pitfalls you encounter when building a data-driven business. For early-stage pharma and biotech companies, comprehensive IP strategies do more than protect innovation in R&D activities. They set the stage for their company’s long-term success – helping to raise funds, attract partners and expand into new markets. Data management questions often arise at the same time.

This series of seminars is aimed at top executives from companies working in the field of life sciences, from medtech to drug development. Attendees will benefit from interactive discussion with the speakers, who will present various case studies from the real-life experiences gathered during their work as consultants.

The first seminar will cover the following topics:

• Licensing ‘basics’ (commonly understated provisions, representations and warranties, liabilities)


• Licensing with public and research institutions


• Data-sharing agreements


• Swiss and EU (GDPR) data protection basics (core concepts, dos and don’ts)


• Collection, use and storage of medical data for R&D
  

AGENDA

• 12:00 Welcome sandwiches and drinks, provided by Biopôle SA


• 12:15 Introductory topic presentation


• 12:30 Presentation of case studies with interactive discussion


• 13:30 Networking coffee with the speakers


• 14:00 End of the event

The speakers will also be available between 14:00 and 17:00 for individual half-hour consulting meetings, please book directly when registering.

 

SPEAKERS

Sevan Antreasyan



Sevan is an expert in the fields of IP law, licensing and other IP transactions in the pharma, medical device, IT and other new technologies sectors. He regularly advises founders and emerging growth companies on IP-related matters and technology agreements. When he is not drafting contracts or emails, Sevan writes Python code.


Emilie Jacot-Guillarmod



Emilie has an intricate knowledge of data protection topics, assisting clients to set up business models and commercial activities that comply with current data protection framework. She also advises companies on IT and outsourcing legal questions. Emilie holds an MBA (INSEAD, 2021).

 

ABOUT LENZ & STAEHLIN

Lenz & Staehelin is a leading law firm in Switzerland with over 200 lawyers, and offices in Geneva, Lausanne and Zurich. It provides legal services in all areas of business law, including corporate and commercial law, mergers and acquisitions, intellectual property, tax, venture capital and data protection. Lenz & Staehelin serves clients in all business sectors and at all stages of development (from incorporation to exit or initial public offering), including emerging growth companies.

The team at Lenz & Staehelin has extensive experience in advising fast growing start-ups in the field of life sciences. They have recently worked with:

• Asceneuron in the out-licensing to Ferrer of the exclusive worldwide rights to develop and commercialise ASN90 in progressive supranuclear palsy (PSP), an orphan neurological disease with a high unmet medical need.


• A biotech research and development organisation and start-up host in Geneva, on various contractual matters, including a data transfer agreement with a Swiss university and data-sharing agreements for medical data.


• A Geneva-based medtech organisation, in the negotiation of contracts for the development of an app that will make extensive use of medical data.


• A Swedish tech start-up, on regulatory and contractual compliance for the preparation of its entry in the Swiss market, including with respect to data scraping and processing in Switzerland.


• Transmutex (a greentech start-up based in Geneva), in all legal matters since its incorporation, including various R&D and collaboration agreements with companies and large research institutions (e.g. CERN).